IL308627A - Methods for the treatment of post-infectious autoimmune diabetes - Google Patents

Methods for the treatment of post-infectious autoimmune diabetes

Info

Publication number
IL308627A
IL308627A IL308627A IL30862723A IL308627A IL 308627 A IL308627 A IL 308627A IL 308627 A IL308627 A IL 308627A IL 30862723 A IL30862723 A IL 30862723A IL 308627 A IL308627 A IL 308627A
Authority
IL
Israel
Prior art keywords
methods
autoimmune diabetes
treating post
infectious autoimmune
post infectious
Prior art date
Application number
IL308627A
Other languages
English (en)
Hebrew (he)
Inventor
Francisco Leon
Original Assignee
Provention Bio Inc
Francisco Leon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provention Bio Inc, Francisco Leon filed Critical Provention Bio Inc
Publication of IL308627A publication Critical patent/IL308627A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
IL308627A 2021-05-24 2022-05-24 Methods for the treatment of post-infectious autoimmune diabetes IL308627A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163192414P 2021-05-24 2021-05-24
PCT/US2022/030780 WO2022251258A1 (en) 2021-05-24 2022-05-24 Methods for treating post infectious autoimmune diabetes
US17/752,650 US20220372146A1 (en) 2021-05-24 2022-05-24 Methods for treating post infectious autoimmune diabetes

Publications (1)

Publication Number Publication Date
IL308627A true IL308627A (en) 2024-01-01

Family

ID=84104472

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308627A IL308627A (en) 2021-05-24 2022-05-24 Methods for the treatment of post-infectious autoimmune diabetes

Country Status (10)

Country Link
US (1) US20220372146A1 (https=)
EP (1) EP4347021A4 (https=)
JP (1) JP2024521164A (https=)
KR (1) KR20240023522A (https=)
CN (1) CN117794572A (https=)
AU (1) AU2022283272A1 (https=)
CA (1) CA3219473A1 (https=)
IL (1) IL308627A (https=)
MX (1) MX2023013849A (https=)
WO (1) WO2022251258A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
EP4532552A4 (en) * 2022-05-24 2025-10-22 Provention Bio Inc METHODS AND COMPOSITIONS FOR PREVENTING OR DELAYING TYPE 1 DIABETES
TW202506177A (zh) * 2023-03-30 2025-02-16 美商普泛森生技公司 減少外源性胰島素使用之方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
SG177907A1 (en) * 2006-06-14 2012-02-28 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
WO2015073833A1 (en) * 2013-11-15 2015-05-21 Pharmacyclics, Inc. Methods for delaying or preventing the onset of type 1 diabetes
WO2020232247A1 (en) * 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CA3148179A1 (en) * 2019-08-20 2021-02-25 Bruce J. Mccreedy Jr. Lymphodepletion dosing regimens for cellular immunotherapies
IL298999A (en) * 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2024520444A (ja) * 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
EP4532552A4 (en) * 2022-05-24 2025-10-22 Provention Bio Inc METHODS AND COMPOSITIONS FOR PREVENTING OR DELAYING TYPE 1 DIABETES

Also Published As

Publication number Publication date
CN117794572A (zh) 2024-03-29
EP4347021A4 (en) 2025-04-23
AU2022283272A1 (en) 2023-12-07
US20220372146A1 (en) 2022-11-24
EP4347021A1 (en) 2024-04-10
WO2022251258A1 (en) 2022-12-01
KR20240023522A (ko) 2024-02-22
JP2024521164A (ja) 2024-05-28
MX2023013849A (es) 2023-12-08
CA3219473A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
IL308627A (en) Methods for the treatment of post-infectious autoimmune diabetes
PL4034308T3 (pl) Sposób sortowania
SI3684377T1 (sl) Postopki zdravljenja okužbe s hepatitisom B
SG11201803578RA (en) A treatment method for silicon-containing wastewater and the utilization method thereof, and a method for preparing a molecular sieve and the system thereof
PL3943153T3 (pl) Układ leczenia wychwytem neutronów
SG10201608532PA (en) Methods, apparatus and devices for authenticating a call session
DK3358463T3 (da) Fremgangsmåde, anordning og system til implementering af hardwareaccelerationsbehandling
EP3389292A4 (en) Method and apparatus for acquiring verification code, and terminal
IL258211A (en) Methods for treating muscular dystrophy
EP3133518A4 (en) Apparatus and method for code obfuscation using indistinguishable identifier conversion
PL3849190T3 (pl) Sposób projektowania składni oraz przyrząd do przeprowadzania kodowania z wykorzystaniem składni
ZA202001141B (en) Zeolite after treatment method
SG11202001074RA (en) Methods for treating muscular dystrophy
PL3317334T3 (pl) Sposób oczyszczania zanieczyszczonych polimerów
SG10202000757YA (en) Confirming method
PT3611502T (pt) Método de pré-tratamento de amostras para injeção utilizando um tubo de microextração
ZA201407781B (en) Adjustable vascular ring, means for treating sfs syndrome and implantable kit comprising such a ring, mould and method for obtaining such a ring
IL277754A (en) A method for the production of spirochetal-converted cyclic ketoanols
IL307937A (en) Treatment methods for muscular dystrophy
IL264485B (en) A method for the production of cyclic ketones converted in spirochetal
GB2580513B (en) Method for preparing modified molecular sieve
GB202010429D0 (en) Methods
GB202303660D0 (en) Proteoform specific process validation
HUE048933T2 (hu) Szavazási eljárás láncolt aláírásokkal
GB201806736D0 (en) Method for virus purification